Futura Medical’s James Barder on what next for Eroxon after UK launch By Proactive Investors
Proactive Investors – Here Futura Medical PLC (LON:FUM) CEO James Barder discusses the UK launch of Eroxon, the company’s over-the-counter erectile dysfunction treatment, with Thomas Warner of Proactive.
Eroxon is now available at Boots stores and online. Barder highlighted the importance of respecting commercial partners’ wishes, noting that updates will be provided reactively rather than proactively.
The product has launched in Belgium and the UK, with significant learnings expected from these different markets. Barder pointed out that the global prescription market for erectile dysfunction treatments is worth between $3-4 billion.
The availability of Eroxon off the shelf in the UK makes it accessible to those who may be too embarrassed to ask a doctor or pharmacist for help.
Barder mentioned that the Middle East, Europe, Latin America, and Asia are being considered for future expansion, and the company remains optimistic about obtaining US regulatory approval for Eroxon as an over-the-counter product before the end of June.
Read more on Proactive Investors UK
Disclaimer
Get The App
Join the millions of people who stay on top of global financial markets with Investing.com.
Download Now
